HIPEC in ovarian cancer: Treatment of a new era or is it the end of the pipeline?

Cascales-Campos, P.A.; Gil, José; Feliciangeli, E.; Parrilla, Pascual

doi:10.1016/j.ygyno.2015.06.012

Cited by 13 publications

(4 citation statements)

References 55 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To improve control of the microscopic component of the disease, the use of hyperthermic intraperitoneal chemotherapy (HIPEC) allows treatment with high doses of the cytostatic, in a single administration. The hyperthermic condition, in addition to the cytotoxic effects on the tumor cell, potentiates the effects of the administered drug [ 8 ]. In 2018, the largest clinical trial in ovarian cancer evaluating HIPEC administration after interval debulking, OVHIPEC-1, was published.…”

Section: Introductionmentioning

confidence: 99%

HIPEC in Ovarian Cancer Is the Future… and Always Will Be? Results from a Spanish Multicentric Survey

González Gil,

Cerezuela Fernández-de Palencia,

Gómez Ruiz

et al. 2023

Cancers

View full text Add to dashboard Cite

Ovarian cancer is the leading cause of death due to gynecological tumors in the female population. Despite optimal first-line treatment, including cytoreduction and platinum-based systemic chemotherapy, recurrences are frequent. The use of hyperthermic intraperitoneal chemotherapy (HIPEC) has been criticized, especially because of the lack of randomized controlled trials (RCTs) with convincing results to support the use of HIPEC in patients with ovarian cancer with peritoneal dissemination. In 2018, the clinical trial published by Van Driel et al. reported improved outcomes in favor of HIPEC treatment with cisplatin. In this study, we conducted a national survey within the Spanish group of peritoneal surgical oncology (Grupo Español de Cirugía Oncológica Peritoneal, GECOP) to explore the impact of the results of this RCT on clinical practice. A total of 33 groups completed the survey. Routine clinical practice was not changed in 28 of the 33 groups (85%) based on the results of the Van Driel trial. Despite the results of this RCT, most groups considered that more RCTs are needed and that, in the future, HIPEC may become the standard of care. In conclusion, the results from RCTs evaluating HIPEC treatment in patients with ovarian cancer has not been transferred to clinical practice.

show abstract

Section: Introductionmentioning

confidence: 99%

HIPEC in Ovarian Cancer Is the Future… and Always Will Be? Results from a Spanish Multicentric Survey

González Gil,

Cerezuela Fernández-de Palencia,

Gómez Ruiz

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…HIPEC has become a useful therapeutic strategy through hyperthermia and peritoneal lavage, debulking achieved by eliminating the residual microscopic component intraperitoneally [12,13]. It can be effectively used for treating peritoneal mesothelioma, pseudomyxoma peritonei, and peritoneal carcinomatosis due to colorectal, gastric, or ovarian cancer.…”

Section: Introductionmentioning

confidence: 99%

“…It can be effectively used for treating peritoneal mesothelioma, pseudomyxoma peritonei, and peritoneal carcinomatosis due to colorectal, gastric, or ovarian cancer. HIPEC with CRS results in higher survival benefit than CRS alone for patients with epithelial ovarian carcinoma, primary advanced ovarian cancer [12,[14][15][16], and recurrent ovarian cancer [14,17]. In 2018, a randomized phase 3 trial compared the efficacy and safety of interval CRS with HIPEC with those of interval CRS without HIPEC [18].…”

Section: Introductionmentioning

confidence: 99%

Effect of hyperthermia on improving neutrophil restoration after intraperitoneal chemotherapy

Huang

Hsu

et al. 2019

International Journal of Hyperthermia

View full text Add to dashboard Cite

Purpose: Intraperitoneal (IP) chemotherapy has several benefits but also can have severe hematologic side effects. We compared the effects of hyperthermic intraperitoneal chemotherapy (HIPEC) and conventional IP chemotherapy on bone marrow suppression and evaluated whether HIPEC increased neutrophil recovery. Methods: HIPEC or IP chemotherapy was administered to ovarian cancer-bearing mice. Bone marrow progenitor cell colony-forming unit (CFU) count, serum cytokine levels, and peripheral leukocyte count after HIPEC and IP chemotherapy were compared. Results: Peripheral neutrophil count, cytokine (G-CSF and CXCL1/KC) levels, and bone marrow progenitor cell CFU count were significantly higher after HIPEC than after IP chemotherapy. Conclusions: Hyperthermia increased the serum neutrophil-recruiting cytokine levels and reduced the magnitude of chemotherapy-induced neutropenia. Thus, HIPEC improved neutrophil and bone marrow recovery compared with conventional IP chemotherapy.

show abstract

“…Nearly 70% to 80% of patients are diagnosed at an advanced stage with peritoneal carcinomatosis or distant metastasis. In patients with complete cytoreduction after surgery, the recurrence rate is >50% [1]. The main treatment for ovarian cancer consists of cytoreductive surgery and platinum-based chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

Hyperthermic intrathoracic chemotherapy with cisplatin for ovarian cancer with pleural metastasis

et al. 2017

View full text Add to dashboard Cite

Intrathoracic metastasis of ovarian cancer has poor prognosis regardless of treatment modality. Recent development of surgical techniques and the new concept of direct infusion of chemotherapeutic agents with hyperthermia could help with the treatment of disseminated diseases in ovarian cancer. Using video-assisted thoracoscopic surgery and intracavitary chemotherapy with hyperthermia, we tried hyperthermic intrathoracic chemotherapy for a case of stage IV high-grade serous ovarian cancer with pleural metastasis. There was no high-grade complication related to the procedure. The patient is alive without disease at 32 months after initial treatment.

show abstract

HIPEC in ovarian cancer: Treatment of a new era or is it the end of the pipeline?

Cited by 13 publications

References 55 publications

HIPEC in Ovarian Cancer Is the Future… and Always Will Be? Results from a Spanish Multicentric Survey

HIPEC in Ovarian Cancer Is the Future… and Always Will Be? Results from a Spanish Multicentric Survey

Effect of hyperthermia on improving neutrophil restoration after intraperitoneal chemotherapy

Hyperthermic intrathoracic chemotherapy with cisplatin for ovarian cancer with pleural metastasis

Contact Info

Product

Resources

About